Confocal microscopy study of pertussis toxin and toxoids on CHO-cells

References

• World Health Organization (WHO). Pertussis vaccines. WHO position paper. Wkly Epidemiol Rec 2005; 80:29 - 40; http://www.who.int/wer/2005/wer8004.pdf PMID: 15715139
   PubMedGoogle Scholar
• Tamura M, Nogimori K, Murai S, Yajima M, Ito K, Katada T, et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21:5516 - 22; http://dx.doi.org/10.1021/bi00265a021; PMID: 6293544
   PubMed Web of Science ®Google Scholar
• Kaslow HR, Burns DL. Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J 1992; 6:2684 - 90; PMID: 1612292
   PubMed Web of Science ®Google Scholar
• Locht C, Coutte L, Mielcarek N. The ins and outs of pertussis toxin. FEBS J 2011; 278:4668 - 82; http://dx.doi.org/10.1111/j.1742-4658.2011.08237.x; PMID: 21740523
   PubMed Web of Science ®Google Scholar
• Sekura RD, Fish F, Manclark CR, Meade B, Zhang YL. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem 1983; 258:14647 - 51; PMID: 6315733
   PubMed Web of Science ®Google Scholar
• Tamura M, Nogimori K, Yajima M, Ase K, Ui M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J Biol Chem 1983; 258:6756 - 61; PMID: 6343381
   PubMed Web of Science ®Google Scholar
• Wong WS, Rosoff PM. Pharmacology of pertussis toxin B-oligomer. Can J Physiol Pharmacol 1996; 74:559 - 64; http://dx.doi.org/10.1139/y96-045; PMID: 8884020
   PubMed Web of Science ®Google Scholar
• Nencioni L, Pizza MG, Volpini G, De Magistris MT, Giovannoni F, Rappuoli R. Properties of the B oligomer of pertussis toxin. Infect Immun 1991; 59:4732 - 4; PMID: 1937835
   PubMed Web of Science ®Google Scholar
• Ui M. In: Moss J, Vaughan M, editors. ADP-ribosylating toxins and G protein. Washington (DC): American Society for Microbiology; 1990; 45-77.
   Google Scholar
• Katada T, Ui M. Islet-activating protein. A modifier of receptor-mediated regulation of rat islet adenylate cyclase. J Biol Chem 1981; 256:8310 - 7; PMID: 7021547
   PubMed Web of Science ®Google Scholar
• Loosmore SM, Zealey GR, Boux HA, Cockle SA, Radika K, Fahim RE, et al. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Infect Immun 1990; 58:3653 - 62; PMID: 2228237
   PubMed Web of Science ®Google Scholar
• Nencioni L, Pizza M, Bugnoli M, De Magistris T, Di Tommaso A, Giovannoni F, et al. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun 1990; 58:1308 - 15; PMID: 2323818
   PubMed Web of Science ®Google Scholar
• Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989; 246:497 - 500; http://dx.doi.org/10.1126/science.2683073; PMID: 2683073
   PubMed Web of Science ®Google Scholar
• Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96:548 - 57; PMID: 7659475
   PubMed Web of Science ®Google Scholar
• Sekura RD, Zhang YL, Roberson R, Acton B, Trollfors B, Tolson N, et al. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J Pediatr 1988; 113:806 - 13; http://dx.doi.org/10.1016/S0022-3476(88)80005-2; PMID: 3263485
   PubMed Web of Science ®Google Scholar
• Gupta RK, Sharma SB, Ahuja S, Saxena SN. Glutaraldehyde inactivated pertussis vaccine: a less histamine sensitizing vaccine. J Biol Stand 1987; 15:159 - 64; http://dx.doi.org/10.1016/0092-1157(87)90038-2; PMID: 3110164
   PubMedGoogle Scholar
• Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996; 14:359 - 68; http://dx.doi.org/10.1016/0264-410X(95)00230-X; PMID: 8735545
   PubMed Web of Science ®Google Scholar
• Nogimori K, Ito K, Tamura M, Satoh S, Ishii S, Ui M. Chemical modification of islet-activating protein, pertussis toxin. Essential role of free amino groups in its lymphocytosis-promoting activity. Biochim Biophys Acta 1984; 801:220 - 31; http://dx.doi.org/10.1016/0304-4165(84)90071-0; PMID: 6541059
   PubMed Web of Science ®Google Scholar
• Fowler S, Byron O, Jumel K, Xing D, Corbel MJ, Bolgiano B. Novel configurations of high molecular weight species of the pertussis toxin vaccine component. Vaccine 2003; 21:2678 - 88; http://dx.doi.org/10.1016/S0264-410X(03)00105-1; PMID: 12744905
   PubMed Web of Science ®Google Scholar
• Petre J, Pizza M, Nencioni L, Podda A, De Magistris MT, Rappuoli R. The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization. Dev Biol Stand 1996; 87:125 - 34; PMID: 8854009
   PubMedGoogle Scholar
• Fowler S, Xing DK, Bolgiano B, Yuen CT, Corbel MJ. Modifications of the catalytic and binding subunits of pertussis toxin by formaldehyde: effects on toxicity and immunogenicity. Vaccine 2003; 21:2329 - 37; http://dx.doi.org/10.1016/S0264-410X(03)00104-X; PMID: 12744863
   PubMed Web of Science ®Google Scholar
• Habeeb AJ, Hiramoto R. Reaction of proteins with glutaraldehyde. Arch Biochem Biophys 1968; 126:16 - 26; http://dx.doi.org/10.1016/0003-9861(68)90554-7; PMID: 4174905
   PubMed Web of Science ®Google Scholar
• Metz B, Kersten GF, Hoogerhout P, Brugghe HF, Timmermans HA, de Jong A, et al. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem 2004; 279:6235 - 43; http://dx.doi.org/10.1074/jbc.M310752200; PMID: 14638685
   PubMed Web of Science ®Google Scholar
• Adsorbed diphtheria-purified pertussis-tetanus combined vaccine. In: Minimum requirements for biological products. Ministry of Health, Japan, Labour and Welfare 2004; 41-9.
   Google Scholar
• Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. In: WHO Technical Report Series 1998; 878:57-72.
   Google Scholar
• Title 21. Pertussis vaccine 620.1. U.S. Code of federal regulations. Washington DC: U.S. Government Printing Office 1983; 58-61.
   Google Scholar
• Pertussis vaccine (acellular, component, adsorbed). Eur Pharmacopoeia 2000; Suppl 1050 - 2
   Google Scholar
• Graf R, Codina J, Birnbaumer L. Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding proteins. Mol Pharmacol 1992; 42:760 - 4; PMID: 1435750
   PubMed Web of Science ®Google Scholar
• Scheuring J, Schramm VL. Pertussis toxin: transition state analysis for ADP-ribosylation of G-protein peptide alphai3C20. Biochemistry 1997; 36:8215 - 23; http://dx.doi.org/10.1021/bi970379a; PMID: 9204866
   PubMed Web of Science ®Google Scholar
• Finck-Barbançon V, Barbieri JT. ADP-ribosylation of alpha i3C20 by the S1 subunit and deletion peptides of S1 of pertussis toxin. Biochemistry 1995; 34:1070 - 5; http://dx.doi.org/10.1021/bi00003a043; PMID: 7827022
   PubMed Web of Science ®Google Scholar
• Cyr T, Menzies AJ, Calver J, Whitehouse LW. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products. Biologicals 2001; 29:81 - 95; http://dx.doi.org/10.1006/biol.2001.0280; PMID: 11580213
   PubMed Web of Science ®Google Scholar
• Yuen CT, Canthaboo C, Menzies JA, Cyr T, Whitehouse LW, Jones C, et al. Detection of residual pertussis toxin in vaccines using a modified ribosylation assay. Vaccine 2002; 21:44 - 52; http://dx.doi.org/10.1016/S0264-410X(02)00446-2; PMID: 12443661
   PubMed Web of Science ®Google Scholar
• Gomez SR, Yuen C-T, Asokanathan C, Douglas-Bardsley A, Corbel MJ, Coote JG, et al. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test. Vaccine 2007; 25:3311 - 8; http://dx.doi.org/10.1016/j.vaccine.2007.01.009; PMID: 17287049
   PubMed Web of Science ®Google Scholar
• Gomez SR, Xing DKL, Corbel MJ, Coote J, Parton R, Yuen C-T. Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid. Anal Biochem 2006; 356:244 - 53; http://dx.doi.org/10.1016/j.ab.2006.05.012; PMID: 16782039
   PubMed Web of Science ®Google Scholar
• Yuen CT, Horiuchi Y, Asokanathan C, Cook S, Douglas-Bardsley A, Ochiai M, et al. An in vitro assay system as a potential replacement for the histamine sensitisation test for acellular pertussis based combination vaccines. Vaccine 2010; 28:3714 - 21; http://dx.doi.org/10.1016/j.vaccine.2010.03.009; PMID: 20307594
   PubMed Web of Science ®Google Scholar
• Nencioni L, Volpini G, Peppoloni S, Bugnoli M, De Magistris T, Marsili I, et al. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun 1991; 59:625 - 30; PMID: 1702767
   PubMed Web of Science ®Google Scholar
• Xing D, Yuen CT, Asokanathan C, Rigsby P, Horiuchi Y. Evaluation of an in vitro assay system as a potential alternative to current histamine sensitization test for acellular pertussis vaccines. Biologicals 2012; 40:456 - 65; http://dx.doi.org/10.1016/j.biologicals.2012.07.013; PMID: 22890129
   PubMed Web of Science ®Google Scholar